



HEALTH CARE TEAM APPOINTMENTS

Throughout your treatment, you may have appointments to remember. Use the space below to record your upcoming health care provider appointments and other scheduled meetings with members of your health care team. When you have kept the appointment, check off the box in the lower right corner.

Date	Time
With whom	
Place or address	
<i>Appointment kept</i> <input type="checkbox"/>	

Date	Time
With whom	
Place or address	
<i>Appointment kept</i> <input type="checkbox"/>	



Date	Time
With whom	
Place or address	
<i>Appointment kept</i> <input type="checkbox"/>	

Date	Time
With whom	
Place or address	
<i>Appointment kept</i> <input type="checkbox"/>	

Date	Time
With whom	
Place or address	
<i>Appointment kept</i> <input type="checkbox"/>	

Date	Time
With whom	
Place or address	
<i>Appointment kept</i> <input type="checkbox"/>	

Please refer to page 2 for Important Safety Information and Indications for SEROQUEL XR.


Please print the [Prescribing Information](#) , including Boxed Warnings and [Medication Guide](#) , and discuss it with your health care provider.

Important Safety Information and Indications for SEROQUEL XR

Elderly patients with dementia-related psychosis (having lost touch with reality due to confusion and memory loss) treated with this type of medicine are at an increased risk of death, compared to placebo (sugar pill). SEROQUEL XR is not approved for treating these patients.



Antidepressants have increased the risk of suicidal thoughts and actions in some children, teenagers, and young adults. Patients of all ages starting treatment should be watched closely for worsening of depression, suicidal thoughts or actions, unusual changes in behavior, agitation, and irritability. Patients, families, and caregivers should pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. Report any change in these symptoms immediately to the doctor. SEROQUEL XR is not approved for patients under the age of 18 years.

- Stop SEROQUEL XR and call your doctor right away if you have some or all of the following symptoms: high fever; stiff muscles; confusion; sweating; changes in pulse, heart rate, and blood pressure. These may be symptoms of neuroleptic malignant syndrome (NMS), a rare and serious condition that can lead to death
- High blood sugar and diabetes have been reported with SEROQUEL XR and medicines like it. If you have diabetes or risk factors such as obesity or a family history of diabetes, your doctor should check your blood sugar before you start taking SEROQUEL XR and also during therapy. If you develop symptoms of high blood sugar or diabetes, such as excessive thirst or hunger, increased urination, or weakness, contact your doctor. Complications from diabetes can be serious and even life threatening
- Increases in triglycerides and in LDL (bad) cholesterol and decreases in HDL (good) cholesterol have been reported with SEROQUEL XR. Your doctor should check your cholesterol levels before you start SEROQUEL XR and during therapy
- Weight gain has been reported with SEROQUEL XR. Your doctor should check your weight regularly
- Tell your doctor about any movements you cannot control in your face, tongue, or other body parts, as they may be signs of a serious condition called tardive dyskinesia (TD). TD may not go away, even if you stop taking SEROQUEL XR. TD may also start after you stop taking SEROQUEL XR
- Other risks include feeling dizzy or lightheaded upon standing, decreases in white blood cells (which can be fatal), or trouble swallowing. Tell your doctor if you experience any of these
- Before starting treatment, tell your doctor about all prescription and nonprescription medicines you are taking. Also tell your doctor if you have or have had low white blood cell count, seizures, abnormal thyroid tests, high prolactin levels, heart or liver problems, or cataracts. An eye exam for cataracts is recommended at the beginning of treatment and every 6 months thereafter
- Since drowsiness has been reported with SEROQUEL XR, you should not participate in activities such as driving or operating machinery until you know that you can do so safely. Avoid becoming overheated or dehydrated while taking SEROQUEL XR. Do not drink alcohol while taking SEROQUEL XR
- Tell your doctor if you are pregnant or intend to become pregnant. Avoid breast-feeding while taking SEROQUEL XR
- The most common side effects are drowsiness, dry mouth, constipation, dizziness, increased appetite, upset stomach, weight gain, fatigue, disturbance in speech and language, and stuffy nose
- Do not stop taking SEROQUEL XR without talking to your doctor. Stopping SEROQUEL XR suddenly may cause side effects

This is not a complete summary of safety information. Please discuss the full [Prescribing Information](#)  with your health care provider.

Indications

SEROQUEL XR is a once-daily tablet approved in adults for (1) add-on treatment to an antidepressant for patients with major depressive disorder (MDD) who did not have an adequate response to antidepressant therapy; (2) acute depressive episodes in bipolar disorder; (3) acute manic or mixed episodes in bipolar disorder alone or with lithium or divalproex; and (4) long-term treatment of bipolar disorder with lithium or divalproex.

Please print the [Prescribing Information](#) , including Boxed Warnings and [Medication Guide](#) , and discuss it with your health care provider.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Patient photos are intended to be representative of typical patients with depression or bipolar disorder and are not of actual patients.

Message for Health Care Professionals:

In order to keep effective drugs available on the market for use by you and your patients, the FDA relies on the voluntary reporting of serious adverse events that you suspect are associated with the use of an FDA-regulated drug. In the interest of patient safety, please be sure to notify the FDA or the manufacturer by contacting the AZ Information Center at 1-800-236-9933 of any such events that you become aware of when discussing this patient questionnaire with your patients or otherwise.

